94 related articles for article (PubMed ID: 16857826)
21. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
22. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
24. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
25. Targeting novel and established therapies for non-small cell lung cancer.
Spicer J; Chowdhury S; Harper P
Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089
[TBL] [Abstract][Full Text] [Related]
26. Targeting protein kinases in cancer therapy.
Fabbro D; García-Echeverría C
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
[TBL] [Abstract][Full Text] [Related]
28. Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.
Khazak V; Kato-Stankiewicz J; Tamanoi F; Golemis EA
Methods Enzymol; 2006; 407():612-29. PubMed ID: 16757356
[TBL] [Abstract][Full Text] [Related]
29. A mathematical model of combination therapy using the EGFR signaling network.
Araujo RP; Petricoin EF; Liotta LA
Biosystems; 2005 Apr; 80(1):57-69. PubMed ID: 15740835
[TBL] [Abstract][Full Text] [Related]
30. Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
Jimeno A; Hidalgo M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):727-35. PubMed ID: 16111472
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials of small molecule inhibitors in high-grade glioma.
Day SE; Waziri A
Neurosurg Clin N Am; 2012 Jul; 23(3):407-16. PubMed ID: 22748653
[TBL] [Abstract][Full Text] [Related]
32. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
[TBL] [Abstract][Full Text] [Related]
33. Receptor signaling in cancer.
Grunt TW
Differentiation; 2007 Nov; 75(9):767-9. PubMed ID: 17999739
[No Abstract] [Full Text] [Related]
34. Growth factors and their relationship to neoplastic and paraneoplastic disease.
Badawi RA; Birns J; Watson T; Kalra L
Eur J Intern Med; 2005 Apr; 16(2):83-94. PubMed ID: 15833673
[TBL] [Abstract][Full Text] [Related]
35. Conformation-specific inhibitors of Raf kinases.
Wang X; Schleicher K
Enzymes; 2013; 34 Pt. B():41-66. PubMed ID: 25034100
[TBL] [Abstract][Full Text] [Related]
36. Targeted molecular therapy of malignant gliomas.
Kesari S; Ramakrishna N; Sauvageot C; Stiles CD; Wen PY
Curr Oncol Rep; 2006 Jan; 8(1):58-70. PubMed ID: 16464405
[TBL] [Abstract][Full Text] [Related]
37. Rounding up the usual suspects: protein kinases as therapeutic targets.
Shears SB
Drug Discov Today; 2005 Feb; 10(4):240-2. PubMed ID: 15708741
[TBL] [Abstract][Full Text] [Related]
38. [Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.].
Nan J; Liu Q; Ding Y; Zhang Z; Gao AC; Zhou Q
Zhongguo Fei Ai Za Zhi; 2009 Dec; 12(12):1316-24. PubMed ID: 20723392
[No Abstract] [Full Text] [Related]
39. Inhibition of farnesyl protein transferase--a review of the recent patent literature.
Doll RJ
IDrugs; 2001 Dec; 4(12):1382-8. PubMed ID: 15931570
[TBL] [Abstract][Full Text] [Related]
40. Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment.
Pandey M; Chandramohan K
World J Surg Oncol; 2003 Jul; 1(1):9. PubMed ID: 12848894
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
